🇺🇸 FDA
Patent

US 8323635

Methods of using interleukin-1 receptor antagonist as a myeloprotective agent

granted A61KA61K31/255A61K31/475

Quick answer

US patent 8323635 (Methods of using interleukin-1 receptor antagonist as a myeloprotective agent) held by GENERAL REGENERATIVES, LTD. expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GENERAL REGENERATIVES, LTD.
Grant date
Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/255, A61K31/475, A61K31/513, A61K31/519